Mrs Joanna Canham

2026

• Morgan, R. D. et al., 2026. Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK. EClinicalMedicine 96 104012. (10.1016/j.eclinm.2026.104012)
• Evans, M. et al. 2026. Correlation between imaging-detected and pathological extranodal extension in a randomised trial in Human Papillomavirus-positive oropharyngeal cancer. British Journal of Cancer 134 , pp.428-438. (10.1038/s41416-025-03291-z)

2025

• Russell, N. H. et al., 2025. Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3 mutated AML. Blood Advances 9 (24), pp.6455-6466. (10.1182/bloodadvances.2025017244)
• Othman, J. et al., 2025. Induction chemotherapy and molecular MRD influence outcomes in KMT2A rearranged AML. Blood 146 (15), pp.1862-1867. (10.1182/blood.2025029556)
• Vrana, E. et al., 2025. ABC-12: exploring the microbiome in patients with advanced biliary tract cancer in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabine. Future Oncology 21 (21), pp.2713-2721. (10.1080/14796694.2025.2539018)
• Potter, N. et al., 2025. Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials. The Lancet Haematology 12 (5), pp.e346-e356. (10.1016/S2352-3026(25)00037-7)

2024

• O’Hara, J. T. et al., 2024. Transoral laser or robotic surgery outcomes for oropharyngeal carcinoma. JAMA Otolaryngology-Head and Neck Surgery 150 (11), pp.1002-1011. (10.1001/jamaoto.2024.3371)
• Othman, J. et al., 2024. Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML. Blood 144 (7), pp.714-728. (10.1182/blood.2024024310)
• Othman, J. et al., 2024. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood 143 (19), pp.1931-1936. (10.1182/blood.2023023096)
• Russell, N. H. et al., 2024. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin with gemtuzumab ozogamicin improves event-free survival in younger patients with newly diagnosed aml and overall survival in patients with npm1 and flt3 mutations. Journal of Clinical Oncology 42 (10), pp.1158-1168. (10.1200/JCO.23.00943)

2023

• Potter, N. et al., 2023. P503: a randomised trial of molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 studies. HemaSphere 7 , pp.857-858. e345570d. (10.1097/01.hs9.0000968920.34557.0d)
• Russell, N. et al., 2023. P484: Gemtuzumab-based induction chemotherapy combined with midostaurin for FLT3 mutated AML. Updated toxicity and interim survival analysis from the NCRI AML19v2 "Midotarg" Pilot Trial. HemaSphere 7 (S3) e13145db. (10.1097/01.HS9.0000968844.13145.db)
• Russell, N. et al., 2023. S134: FLAG‐Ida combined with gemtuzumab ozogamicin (GO) reduced MRDlevels and improved overall survival in NPM1mut AML independent of FLT3 and MRD status, results from the AML19 trial [Abstract]. HemaSphere 7 , pp.76-78. e252478c. (10.1097/01.hs9.0000967448.25247.8c)
• Othman, J. et al., 2023. A randomised comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial. Blood Advances 7 (16), pp.4539-4549. (10.1182/bloodadvances.2023010276)

2022

• Othman, J. et al., 2022. Genomic correlates of outcome in a randomised comparison of CPX-351 and FLAG-Ida in high-risk acute myeloid leukaemia and myelodysplastic syndrome: results from the UK NCRI AML19 Trial. Presented at: 64th ASH Annual Meeting and Exposition New Orleans, Louisiana 10-13 December 2022. Vol. 140.Vol. S1. American Society of Hematology. , pp.1036-1038. (10.1182/blood-2022-159433)
• Russell, N. H. et al., 2022. FLAG-Ida combined with Gemtuzumab Ozogamicin (GO) improves event free survival in younger patients with newly diagnosed Acute Myeloid Leukaemia (AML) and shows an overall survival benefit in NPM1 and FLT3 mutated subgroups. Results from the UK NCRI AML19 trial. Blood 140 (S1), pp.526-528. (10.1182/blood-2022-162377)

2021

• Mukherjee, S. et al., 2021. Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial. European Journal of Cancer 153 , pp.153-161. (10.1016/j.ejca.2021.05.020)

2017

• Mukherjee, S. et al., 2017. NEOSCOPE: a randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma. European Journal of Cancer 74 , pp.38-46. (10.1016/j.ejca.2016.11.031)

2016

• Canham, J. 2016. The development of an intervention to support job retention and return to work for individuals with a diagnosis of bipolar disorder. PhD Thesis , Cardiff University.

2015

• Noble, S. I. et al. 2015. A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT). Health Technology Assessment 19 (83), pp.1-94. (10.3310/hta19830)
• Mukherjee, S. et al., 2015. NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma. BMC Cancer 15 (1) 48. (10.1186/s12885-015-1062-y)

2013

• Cohen, D. et al. 2013. Factors that impact on medical student wellbeing: perspectives of risks. Project Report.[Online].Gneral Medical Council. Available at: https://www.gmc-uk.org/about/what-we-do-and-why/data-and-research/research-and-insight-archive/factors-that-impact-on-medical-student-wellbeing.

2012

• Cohen, D. A. et al. 2012. The return to work discussion: A qualitative study of the line manager conversation about return to work and the development of an educational programme. Journal of Rehabilitation Medicine 44 (8), pp.677-683. (10.2340/16501977-0996)
• Cohen, D. A. et al. 2012. Shifting attitudes: the National Education Programme for work and health. Occupational Medicine 62 (5), pp.371-374. (10.1093/occmed/kqs081)